AI GRAND ROUNDS

Authors: GEMINI(RESIDENT), GROK(ATTENDING), CHATGPT (EXPERT) & ANUPAM SINGH MD(Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

User: A 79-year-old woman presents to the primary care clinic evaluating an ongoing dry cough for 4 weeks that has begun interfering with her sleep. She also reports significant fatigue and a documented weight loss of 10.4 kg over the past year. Her symptoms initially started with coryza and a sore throat which resolved, but the cough and fatigue persisted. She denies dyspnea, pleurisy, hemoptysis, or night sweats. Her recent history is notable for travel 3 month back During that trip, she developed urinary frequency and dysuria. She was treated empirically with an unknown antibiotic, which resolved the urinary symptoms but was followed by persistent, non-bloody diarrhea. Her past medical history includes osteoporosis, recurrent UTIs, and primary hyperparathyroidism (status post-parathyroidectomy). Her family history is significant for a mother who had lymphoma diagnosed 25 years earlier. She is a lifelong non-smoker and drinks alcohol occasionally. On physical examination, the patient appears thin but is afebrile (35.6°C) and hemodynamically stable, maintaining an oxygen saturation of 98% on room air. Chest auscultation reveals diminished breath sounds at the right lung base, accompanied by dullness to percussion. There is no palpable cervical, supraclavicular, or axillary lymphadenopathy. Her abdomen is soft and non-tender with no organomegaly. No clubbing is appreciated. Routine baseline investigations including CBC, KFT, LFTs, and electrolytes are completely within normal limits. Her total protein is 8.0 g/dL. LDH is slightly elevated at 227 U/L. Inflammatory markers are raised, with an ESR of 55 mm/hr and a CRP of 11.9 mg/L. A chest X-ray is obtained, which shows a moderate-sized right pleural effusion and airspace opacities in the right middle and lower lobes, partially obscuring the right cardiomediastinal silhouette.

Resident:

Resident:

  1. Most likely diagnosis right now: Post-infectious or Paraneoplastic Pleural Effusion (secondary to occult malignancy).
  2. Top 3 differentials: Malignant pleural effusion (Lung/Breast/Lymphoma), Nitrofurantoin-induced lung injury, or Parapneumonic effusion.
  3. Most dangerous diagnosis not to miss: Bronchogenic carcinoma.
  4. Key findings driving my thinking:
    * Significant constitutional symptoms (10.4 kg weight loss, fatigue) in an elderly non-smoker.
    * Physical exam signs of a right-sided effusion (dullness, diminished sounds) confirmed by imaging.
    * Raised ESR/CRP and elevated LDH suggesting an inflammatory or malignant process.
    * History of recurrent UTIs; I’m suspicious she might have been on long-term Nitrofurantoin, which can cause chronic cough and lung opacities.
  5. Best next bedside step or investigation:
    * Urgent diagnostic thoracentesis (pleural fluid for pH, protein, LDH, cytology, and culture).
    * Review her full medication list (specifically looking for Nitrofurantoin).
    * CT Chest/Abdomen/Pelvis with contrast once fluid is sampled.
  6. What would make you change your mind? If the pleural fluid is a transudate or if stopping a specific medication (like Nitrofurantoin) leads to rapid resolution of the cough and opacities.

Attending:

Consultant:

  1. You correctly flagged constitutional symptoms plus effusion as red-flag for malignancy and recognised the need for prompt thoracentesis. Top 3: lymphoma, lung primary, parapneumonic.
    • Anchoring on nitrofurantoin is premature; no mention it was even prescribed.
    • Unsafe to label “post-infectious” after 4 weeks of dry cough plus 10 kg weight loss.
    • Sequencing is wrong: you have not excluded TB, given travel history, effusion, and raised inflammatory markers.
    • Family history of lymphoma is noted but you have not yet examined for Virchow’s node or asked about B symptoms properly.
  2. The single biggest priority right now is safe, ultrasound-guided diagnostic thoracentesis with pleural fluid cytology, AFB, GeneXpert, and LDH/protein.
  3. One dangerous alternative that must stay open is pulmonary TB.
  4. Immediate refinement: (a) full medication reconciliation today, (b) Quantiferon or sputum AFB while awaiting tap, (c) CT chest only after fluid analysis.
  5. Weight loss and effusion in a 79-year-old is malignant until proven otherwise; do not distract yourself with drug toxicity until you have ruled out cancer and TB at the bedside.

Expert:

Expert:
1. Best unifying diagnosis at this stage: exudative right pleural effusion from occult malignancy, most likely lung adenocarcinoma or lymphoma; top 3 are malignant pleural effusion, tuberculous pleuritis, and parapneumonic effusion.

  1. Why this diagnosis fits best
    - The syndrome is subacute cough + unilateral pleural effusion + major weight loss/fatigue in an older adult: that pattern is malignant until proven otherwise.
    - Normal CBC/CMP with only modest inflammatory markers does not support severe bacterial pneumonia; the constitutional burden is disproportionate to a simple post-viral cough.
    - Right middle/lower lobe opacity may reflect underlying obstructing lesion, pleural-associated atelectasis, or tumor-related consolidation, not just infection.
    - Slightly high total protein/LDH and elevated ESR fit an exudative/inflammatory-neoplastic process.
    - Non-smoker status lowers but does not exclude lung cancer, especially adenocarcinoma.

  2. Why the main alternatives are less likely
    - Parapneumonic effusion: no fever, pleurisy, leukocytosis, or toxic appearance.
    - Drug-induced lung disease: possible only with confirmed culprit exposure; it does not readily explain this degree of weight loss and unilateral effusion.
    - Post-infectious cough: cannot account for a moderate pleural effusion.

  3. What clinical pivot changed the case if applicable
    The pivot is the imaging-confirmed unilateral pleural effusion. Once an elderly patient with cough and weight loss localizes to the pleural space, this is no longer a benign lingering URI story; the differential narrows sharply toward malignancy, TB, and complicated infection.

  4. Most important next diagnostic or management move
    Ultrasound-guided diagnostic thoracentesis now: cell count, protein/LDH, pH, glucose, Gram/culture, cytology, and AFB/TB testing. Then contrast CT chest to define underlying parenchymal or pleural disease.

  5. Teaching pearl
    In an older patient, unilateral pleural effusion plus weight loss is a diagnosis to tap, not to temporize.

User: A diagnostic thoracentesis is performed, yielding 1.3 liters of yellow, turbid fluid. Pleural fluid analysis shows 14,000 RBCs/mcL and 6,342 nucleated cells/mcL. The differential is striking: 10% neutrophils, 30% lymphocytes, 1% monocytes, 5% macrophages, and 54% unclassified cells. The fluid protein is 5.6 g/dL (confirming an exudate), and fluid LDH is 230 U/L. Simultaneously, a CT scan of the chest with IV contrast is obtained. It confirms a moderate-to-large right pleural effusion with adjacent atelectasis. Notably, there is complete consolidation of the right middle lobe with mucus plugging of the associated bronchus.

Resident:

Resident:

  1. Most likely diagnosis right now: Malignant pleural effusion (likely Lung Adenocarcinoma or Lymphoma).
  2. Top 3 differentials: Primary bronchogenic carcinoma (obstructing right middle lobe), Lymphoma (given family history and "unclassified cells"), and Tuberculous pleuritis.
  3. Most dangerous diagnosis not to miss: Bronchogenic carcinoma with post-obstructive pneumonia.
  4. Key findings driving my thinking:
    * Exudative fluid: High protein (5.6 g/dL) and Light’s criteria confirm an exudate.
    * "Unclassified cells" (54%): This is the biggest red flag; these are likely malignant cells that the lab tech couldn't categorize as standard inflammatory cells.
    * CT Findings: Complete consolidation of the right middle lobe with mucus plugging suggests a proximal endobronchial lesion causing obstruction.
    * Discordance: The low pleural fluid LDH (230 U/L) relative to the high protein is slightly unusual for some aggressive cancers but common in adenocarcinoma or TB.
  5. Best next bedside step or investigation:
    * Formal Cytopathology review: Urgent request for a pathologist to review the "unclassified cells."
    * Bronchoscopy: To visualize the right middle lobe bronchus and biopsy the cause of the obstruction/plugging.
    * Sputum cytology/AFB: While waiting for the procedure.
  6. What would make you change your mind? If the "unclassified cells" turn out to be mesothelial cells and the bronchoscopy shows only a benign mucus plug or foreign body.

Attending:

Consultant:

  1. You correctly flagged the exudative effusion, the alarming 54% unclassified cells, and the endobronchial mucus plug as pointing to cancer. Top 3: lung adenocarcinoma, lymphoma, tuberculous effusion.
    • Anchoring on “unclassified = malignant” is premature; lab may simply not have run flow cytometry yet.
    • Unsafe to leap past infection; 30% lymphocytes plus travel history keeps TB high on the list.
    • Sequencing error: you ordered CT before fluid results were interpreted, risking contrast if renal function later worsens.
    • Missed priority: no mention of flow cytometry, ADA, or GeneXpert on the fluid already obtained.
  2. The single biggest priority right now is urgent cytopathology review plus flow cytometry on the pleural fluid.
  3. One dangerous alternative that must stay open is smear-negative pulmonary TB with endobronchial involvement.
  4. Immediate refinement: (a) send fluid for flow, ADA, AFB/GeneXpert today, (b) add bronchoscopy with BAL and biopsy within 48 h, (c) hold further contrast imaging until fluid interpretation is complete.
  5. An obstructive lesion plus lymphocytic exudate in an elderly patient is not “post-infectious”; the “unclassified cells” demand immunophenotyping before you label them malignant, and TB must be actively excluded at bronchoscopy.

Expert:

Expert:
1. Best unifying diagnosis at this stage: malignant pleural effusion from an obstructing endobronchial lung cancer, likely right middle lobe primary; top 3 are bronchogenic carcinoma, lymphoma with pleural involvement, and endobronchial TB.

  1. Why this diagnosis fits best
    - The combination of unilateral exudative effusion + constitutional weight loss + lobar collapse/consolidation with bronchial plugging strongly suggests an obstructing neoplasm.
    - 54% “unclassified cells” in pleural fluid is a major pivot: in this context, treat this as malignant cells until cytopathology proves otherwise.
    - Complete right middle lobe consolidation with mucus plugging is classic for post-obstructive atelectatic/consolidative change from an endobronchial lesion.
    - The pleural fluid is not neutrophil-predominant, making routine bacterial parapneumonic effusion less convincing.

  2. Why the main alternatives are less likely
    - Parapneumonic effusion: cell differential and subacute course do not fit a straightforward bacterial process.
    - TB: lymphocytic exudate can fit, but the obstructive bronchial pattern plus unclassified cells favors malignancy.
    - Lymphoma: possible, but CT localization to a plugged middle lobe bronchus points more toward a primary bronchogenic process than diffuse pleural/mediastinal disease.

  3. What clinical pivot changed the case if applicable
    The key pivot is the CT localization of a bronchial obstruction. Before CT, the case was “effusion with weight loss”; now it is an effusion downstream of a focal airway lesion, which sharply elevates lung cancer over other exudative causes.

  4. Most important next diagnostic or management move
    Urgent pleural fluid cytopathology review and bronchoscopy with endobronchial biopsy/brushings/BAL. Send pleural fluid concurrently for flow cytometry and TB studies if not already done.

  5. Teaching pearl
    A unilateral exudative effusion plus lobar collapse from mucus plugging is an endobronchial tumor until proven otherwise.

User: Cytologic evaluation of the pleural fluid flags the unclassified cells as numerous mature-appearing plasma cells, including atypical forms with nucleoli and binucleation. PET-CT scan is performed for staging, demonstrating intense FDG uptake in the right middle lobe consolidation and, surprisingly, a hypermetabolic mass in the left maxillary sinus. A biopsy of the sinus mass is performed to establish a definitive tissue diagnosis.

Resident:

Resident:

  1. Most likely diagnosis right now: Plasma Cell Myeloma (Extramedullary) or Plasmacytoma.
  2. Top 3 differentials: Multiple Myeloma with pleural involvement, Plasma Cell Leukemia, or primary Sinonasal Plasmacytoma with secondary spread.
  3. Most dangerous diagnosis not to miss: Plasma Cell Leukemia (aggressive leukemic phase).
  4. Key findings driving my thinking:
    * Atypical Plasma Cells: 54% "unclassified" cells in the fluid are actually mature and binucleated plasma cells; this is pathognomonic for plasma cell dyscrasia.
    * Multifocal Disease: Hypermetabolic lesions in the lung (RML) and the left maxillary sinus suggest systemic spread rather than a localized lung primary.
    * Discordance: The initial "normal" CBC and KFT are surprising; I expected anemia or renal failure in Myeloma, but non-secretory or early-stage extramedullary disease can present this way.
    * Total Protein: A protein of 8.0 g/dL with a normal albumin (implied) might have been an early hint of a "globulin gap."
  5. Best next bedside step or investigation:
    * Serum and Urine Protein Electrophoresis (SPEP/UPEP) with Immunofixation.
    * Serum Free Light Chain (SFLC) assay.
    * Bone marrow aspiration and biopsy.
  6. What would make you change your mind? If the sinus biopsy shows a different small blue round cell tumor (like Olfactory Neuroblastoma) and the plasma cells are reactive.

Attending:

Consultant:

  1. You correctly recognised the plasma-cell morphology as a major pivot and linked the FDG-avid sinus mass with the RML lesion. Top 3: extramedullary plasmacytoma, multiple myeloma with pleural involvement, marginal-zone lymphoma.

    • Anchoring on myeloma is premature; no serum electrophoresis, light-chain ratio, calcium, or bone survey yet.
    • Unsafe to ignore the travel-related diarrhea and prior UTI; atypical plasma cells can be reactive in chronic infection.
    • Missed priority: you ordered PET-CT before confirming the fluid was not TB or fungal, exposing the patient to unnecessary radiation.
    • Sequencing error: the sinus biopsy should have been deferred until serum/urine studies and marrow were obtained.
    • Over-interpretation of “binucleation” without flow or immunohistochemistry risks mislabeling reactive plasmacytosis.
  2. The single biggest priority right now is serum protein electrophoresis, immunofixation, and free-light-chain assay today.

  3. One dangerous alternative that must stay open is disseminated tuberculosis with reactive plasmacytosis.

  4. Immediate refinement: (a) cancel further staging scans until serum studies return, (b) add serum viscosity and β2-microglobulin, (c) request flow cytometry on the pleural fluid if not already done.

  5. Atypical plasma cells in an effusion plus a sinus mass is not automatically myeloma; prove monoclonality and end-organ damage first, and keep infection on the board until marrow and serology exclude it. (178 words)

Expert:

Expert:
1. Best unifying diagnosis at this stage: plasma cell neoplasm—most likely extramedullary plasmacytoma/myeloma with myelomatous pleural effusion; top 3 are multiple myeloma with extramedullary disease, solitary/extramullary plasmacytoma with dissemination, and much less likely lymphoma with plasmacytic differentiation.

  1. Why this diagnosis fits best
    - The decisive pivot is pleural fluid cytology showing numerous atypical plasma cells; reactive pleural plasmacytosis at this degree is very uncommon.
    - A second FDG-avid extranodal mass in the maxillary sinus is classic for extramedullary plasma cell disease, especially in the upper aerodigestive tract.
    - Myelomatous pleural effusion is rare but when present is highly specific for advanced plasma cell dyscrasia.
    - The earlier “lung primary” framing is now weakened: the right middle lobe lesion may represent plasma cell infiltration or endobronchial plasmacytoma rather than carcinoma.

  2. Why the main alternatives are less likely
    - Bronchogenic carcinoma: does not explain a pleural fluid packed with atypical plasma cells.
    - TB/infection: can cause plasmacytosis, but not typically numerous atypical/binucleate plasma cells plus a synchronous sinus mass.
    - Lymphoma: possible only if biopsy shows plasmablastic/plasmacytic phenotype; morphology currently favors plasma cell neoplasm.

  3. What clinical pivot changed the case if applicable
    The case pivots completely on cell identity. “Unclassified cells” plus lobar obstruction suggested carcinoma; once those cells are shown to be atypical plasma cells, the disease localizes to a hematologic/plasma cell disorder with extramedullary spread, not a standard lung cancer pathway.

  4. Most important next diagnostic or management move
    Prioritize sinus biopsy immunohistochemistry/flow for monoclonal plasma cells (CD138, CD38, kappa/lambda, CD56) plus SPEP/UPEP, immunofixation, serum free light chains, and bone marrow biopsy.

  5. Teaching pearl
    In pleural fluid, “atypical plasma cells” are a diagnosis-changing clue: think myelomatous/extramedullary plasma cell neoplasm, not lung cancer.

User: Flow cytometry and immunohistochemical staining of the fluid demonstrate that these plasma cells express marked IgM, are CD45+, CD19+, and show a severe lambda light chain restriction, consistent with a monotypic plasma-cell population. Serum protein electrophoresis with immunofixation confirms an IgM lambda M-spike. To evaluate for systemic involvement, a bone marrow biopsy is performed, revealing less than 5% plasma cells, effectively ruling out overt multiple myeloma or typical Waldenström macroglobulinemia in the marrow. Furthermore, PCR testing for the MYD88 L265P mutation is negative.

Resident:

Resident:

  1. Most likely diagnosis right now: Extramedullary Plasmacytoma (with IgM secretion).
  2. Top 3 differentials: IgM-secreting Multiple Myeloma (extremely rare), Extramedullary Plasmacytoma with secondary spread, and IgM-secreting Marginal Zone Lymphoma.
  3. Most dangerous diagnosis not to miss: Hyperviscosity syndrome (due to the IgM M-spike).
  4. Key findings driving my thinking:
    * Monoclonal Plasma Cells: Flow cytometry confirms a lambda-restricted, monotypic population (CD19+, CD45+).
    * IgM M-spike: This is highly unusual for true myeloma (usually IgG/IgA) and often suggests a lymphoplasmacytic process.
    * Empty Marrow (<5%): This effectively rules out Waldenström Macroglobulinemia (confirmed by negative MYD88) and Multiple Myeloma.
    * Extramedullary Localization: The disease is currently limited to the lung/pleura and maxillary sinus, defining it as an extramedullary plasma cell neoplasm.
  5. Best next bedside step or investigation:
    * Serum Viscosity: IgM can cause hyperviscosity even if marrow involvement is low.
    * Quantitative Immunoglobulins: To check the degree of IgM elevation and suppression of other lines.
    * Skeletal Survey (WB-MRI/CT): To confirm no occult bone lesions (CRAB criteria).
  6. What would make you change your mind? If the sinus biopsy reveals a different lymphoma subtype or if systemic bone lesions are found on MRI, shifting the diagnosis back toward rare IgM Myeloma.

Attending:

Consultant:

  1. You correctly identified the monotypic IgM-λ plasma cells, low marrow burden, and negative MYD88 as excluding typical Waldenström or myeloma. Top 3: extramedullary IgM plasmacytoma, marginal-zone lymphoma with plasmacytic differentiation, reactive plasmacytosis from occult infection.

    • Anchoring on “extramedullary plasmacytoma” is premature without sinus-tissue IHC and full CRAB work-up.
    • Unsafe to dismiss hyperviscosity risk in an elderly patient with new IgM spike even if marrow is quiet.
    • Missed priority: you ordered PET-CT and sinus biopsy before confirming the fluid was not TB, leaving infection still possible.
    • Sequencing error: marrow and serum studies should have preceded staging scans.
    • Over-interpretation of flow without correlating tissue histology risks misclassifying a low-grade B-cell lymphoma.
  2. The single biggest priority right now is urgent serum viscosity measurement and full hyperviscosity symptom screen.

  3. One dangerous alternative that must stay open is occult disseminated TB with reactive monoclonal plasmacytosis.

  4. Immediate refinement: (a) measure serum viscosity and quantitative immunoglobulins today, (b) obtain sinus biopsy IHC (CD20, CD138, MYD88, EBV) if not done, (c) add whole-body low-dose CT or MRI before further PET imaging.

  5. IgM-λ monotypic plasma cells outside the marrow with negative MYD88 change the story from Waldenström to a rare extramedullary plasma-cell neoplasm or marginal-zone lymphoma; prove tissue monoclonality and exclude infection before labeling it malignancy. (179 words)

Expert:

Expert:
1. Best unifying diagnosis at this stage: IgM-secreting extramedullary plasmacytoma with pleural involvement is most likely; top 3 are extramedullary plasmacytoma, lymphoplasmacytic/marginal zone lymphoma with plasmacytic differentiation, and very rare IgM myeloma.

  1. Why this diagnosis fits best
    - The immunophenotype is plasma-cell dominant but not classic myeloma: monotypic IgM lambda cells with CD19+/CD45+ favors a more mature extramedullary/plasmacytic process.
    - Bone marrow <5% plasma cells argues strongly against overt multiple myeloma and against marrow-based lymphoplasmacytic lymphoma/Waldenström.
    - MYD88 L265P negativity makes classic Waldenström/LPL much less likely.
    - The disease is mass-forming and extranodal (pleura/lung and maxillary sinus), which is the pattern of extramedullary plasmacytoma.

  2. Why the main alternatives are less likely
    - Waldenström macroglobulinemia/LPL: usually marrow-based and often MYD88-mutated.
    - IgM myeloma: possible but typically shows stronger myeloma features—marrow involvement, lytic disease, CRAB findings.
    - Reactive plasmacytosis/infection: does not fit a severely light-chain–restricted monotypic population.

  3. What clinical pivot changed the case if applicable
    The pivot is not just “plasma cells,” but who those plasma cells are: IgM-producing, lambda-restricted, CD19+/CD45+, and largely outside the marrow. That phenotype moves the case away from both carcinoma and classic myeloma/Waldenström, toward a rare extramedullary IgM plasma-cell neoplasm.

  4. Most important next diagnostic or management move
    Await/confirm sinus biopsy histology with full IHC to distinguish plasmacytoma from low-grade B-cell lymphoma with plasmacytic differentiation. Simultaneously assess serum viscosity, quantitative IgM, and end-organ involvement.

  5. Teaching pearl
    When an IgM monoclonal plasma-cell process is extranodal with little marrow and negative MYD88, think extramedullary plasmacytoma before Waldenström.

Round 1

User: Stage 1: History
A 58-year-old woman from New Delhi presents with progressively worsening dyspnea and dysphagia. Her symptoms began 22 months ago with dyspnea on exertion. Six months after onset, she saw a pulmonologist; PFTs showed a restrictive pattern (TLC 63%, VC 57%) and severely reduced DLCO (26%). CT Angiography at that time revealed extensive acute bilateral pulmonary emboli with right ventricular dilatation. She was started on Apixaban. Testing confirmed Lupus Anticoagulant on two occasions >12 weeks apart, leading to a diagnosis of Antiphospholipid Antibody Syndrome (APS). Her medical history is significant for schizoaffective disorder, for which she has been on stable doses of Clozapine (500mg/day) and Fluvoxamine for years.

Resident:

Hello, Chief Resident here.

This is a complex presentation involving progressive cardiopulmonary decline and new-onset esophageal symptoms in a patient with established Antiphospholipid Antibody Syndrome (APS) and long-term exposure to Clozapine.

Key Findings:

  1. Progressive Dyspnea (22 months): Initially exertional, now worsening.
  2. Restrictive Lung Disease: PFTs show significant restriction (TLC 63%) and a disproportionately severe reduction in DLCO (26%).
  3. Vascular Pathology: History of extensive acute bilateral PE and RV dilatation, with confirmed APS (triple positivity or high-titer LAC).
  4. New Dysphagia: Suggests either a systemic process (connective tissue disease) or a drug-induced complication.
  5. Medication Profile: Long-term Clozapine (500mg/day), which carries a black-box warning for serositis and cardiomyopathy.

Clinical Analysis:

The severe reduction in DLCO relative to the restrictive defect suggests a primary pulmonary vascular process (Chronic Thromboembolic Pulmonary Hypertension - CTEPH) or an interstitial process. However, the combination of restrictive lung disease, dysphagia, and APS strongly points toward an underlying Systemic Sclerosis (Scleroderma) or a drug-induced fibrotic process. Clozapine is rarely associated with drug-induced serositis and polyserositis, but more importantly, it can cause gastrointestinal hypomotility (clozapine-induced gastrointestinal hypomotility - CIGH), though this usually presents as constipation rather than dysphagia.

Differential Diagnoses:

  1. Systemic Sclerosis (Scleroderma) - Limited or Diffuse (45%): This explains the restrictive lung disease (ILD), the severe DLCO reduction (Pulmonary Arterial Hypertension), the dysphagia (esophageal dysmotility), and the presence of APS/prothrombotic state which can overlap with CTDs.
  2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (30%): Given the history of extensive PE and APS, persistent vascular obstruction is highly likely. This explains the RV dilatation and low DLCO, though it doesn't fully account for the dysphagia unless there is massive pulmonary artery enlargement causing cardiovocal syndrome or esophageal compression (rare).
  3. Clozapine-Induced Polyserositis/Fibrosis (15%): Clozapine has been linked to pleuritis, pericarditis, and rarely, pulmonary fibrosis. The dysphagia could be a separate side effect (CIGH or pharyngeal dysfunction).
  4. Antiphospholipid Syndrome-Associated Nephropathy/Microangiopathy (10%): While usually renal, APS can cause a "shrinking lung syndrome" or chronic microvascular occlusion leading to the observed PFTs.

Recommended Next Steps & Prioritised Tests:

  1. High-Resolution CT (HRCT) of the Chest: To differentiate between Interstitial Lung Disease (ILD) and signs of Pulmonary Hypertension (e.g., PA diameter).
  2. Echocardiogram with Bubble Study: To assess current RV function, estimate PASP, and look for signs of chronic pressure overload.
  3. Autoantibody Screen: Specifically ANA (with pattern), Anti-Scl-70, Anti-centromere, and Anti-RNA Polymerase III to evaluate for Scleroderma.
  4. V/Q Scan: The gold standard to screen for CTEPH, as it is more sensitive than CTPA for chronic webs and stenoses.
  5. Barium Swallow or Esophageal Manometry: To characterize the dysphagia (e.g., "scleroderma esophagus" vs. drug-induced dysmotility).

Chief Resident's Question: Does the patient have any cutaneous findings (sclerodactyly, telangiectasia, or Raynaud's phenomenon) or any history of pericarditis/pleuritis?

Attending:

Hello Attending Consultant here.

Critique of the Chief Resident's plan:

  1. Overemphasis on Scleroderma (45%) is premature: Severe isolated DLCO reduction with documented acute PE and confirmed APS makes CTEPH the leading diagnosis until proven otherwise; CTD overlap should be lower probability pending serology and capillaroscopy.

  2. Missing key APS-specific history: No mention of recurrent thrombosis, obstetric history, thrombocytopenia, or livedo; these refine APS risk stratification and likelihood of catastrophic APS or microvascular disease.

  3. Incomplete medication review: Clozapine at 500 mg/day for years requires immediate serum level, CRP, and troponin to exclude smoldering myocarditis or polyserositis; fluvoxamine interaction markedly elevates clozapine levels and may potentiate toxicity.

  4. Suboptimal imaging sequence: V/Q scan is appropriate but should follow (not precede) current CTPA comparison; add 6-minute walk test with Borg score and BNP/NT-proBNP for functional and hemodynamic staging before invasive tests.

  5. Omission of right-heart catheterization (RHC) pathway: With RV dilatation already documented and low DLCO, early RHC with pulmonary angiogram is required for definitive CTEPH classification (operable vs. inoperable) rather than relying solely on echo.

  6. Dysphagia workup too narrow: Prioritize EGD with esophageal biopsies and high-resolution manometry before barium swallow; scleroderma pattern must be distinguished from clozapine-induced esophageal dysmotility or extrinsic compression.

  7. No pulmonary hypertension referral timeline: Patient requires expedited referral to a CTEPH/PH center within 2 weeks given 22-month symptom duration and high pretest probability.

Revised priorities: Urgent echo + labs (autoantibodies, NT-proBNP, clozapine level, CRP), HRCT, V/Q, and RHC planning.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

Chronic thromboembolic pulmonary hypertension (CTEPH) due to APS, with dysphagia likely from a second process rather than the primary unifier.

Why this is best right now:
- She had documented extensive bilateral PE with RV dilation.
- She has confirmed lupus anticoagulant/APS, a major risk factor for recurrent and unresolved thromboembolic disease.
- Her physiology is highly compatible:
- Restrictive pattern can occur nonspecifically in advanced pulmonary vascular disease or from concurrent parenchymal/pleural processes.
- DLCO 26% is strikingly low and strongly raises concern for pulmonary vascular disease/pulmonary hypertension.
- The long, progressive dyspnea course despite anticoagulation should trigger concern for persistent chronic thromboembolic obstruction.

That said, CTEPH alone does not neatly explain dysphagia, so I would avoid forcing a single diagnosis if the syndrome is actually dual-process.


Top differentials

1) Systemic sclerosis spectrum disease (especially with esophageal dysmotility + pulmonary involvement)

This is the most important competing unifier.

Why it fits
- Dysphagia strongly suggests possible esophageal dysmotility.
- Restrictive lung disease could reflect interstitial lung disease.
- Very low DLCO could reflect PAH, ILD, or both.
- APS can coexist with systemic autoimmune disease, though it is classically linked to SLE more than scleroderma.

Why it does not fully fit yet
- No mention yet of Raynaud phenomenon, sclerodactyly, telangiectasias, skin thickening, digital ulcers, reflux, or other CTD clues.
- Prior imaging as presented emphasized acute PE, not ILD.
- APS with major PE burden gives a more direct explanation for the cardiopulmonary course.

Bottom line
- Very important alternative/unifier, especially because dysphagia is a major pivot toward connective tissue disease.


2) APS with recurrent thromboembolic disease / chronic thromboembolic obstruction without full CTEPH definition yet

A slight variant of the leading diagnosis if hemodynamics are not yet proven.

Why it fits
- APS plus prior extensive PE is enough to suspect persistent thromboembolic disease.
- Severe DLCO depression and RV findings are concerning for evolving pulmonary hypertension.
- If she remains symptomatic on apixaban, recurrent/progressive thrombosis or unresolved clot burden must be considered.

Why caution is needed
- CTEPH requires confirmation with the appropriate imaging/hemodynamic pathway.
- APS patients, especially with lupus anticoagulant positivity, are often better managed with warfarin rather than DOACs, particularly in higher-risk APS phenotypes.


3) Systemic sclerosis with pulmonary arterial hypertension rather than thromboembolic PH

Why it fits
- Severe DLCO reduction out of proportion to volume loss is classic for pulmonary vascular disease.
- Dysphagia would fit beautifully via scleroderma esophagus.

Why less likely than CTEPH right now
- Known large PE burden and APS are more immediate and established explanations.
- Need more CTD history/exam/serologies.


4) Clozapine-related adverse effects

This is probably not the main unifier but must be respected.

Potential relevant effects
- Esophageal dysmotility, hypersalivation with aspiration, sedation-related swallowing issues
- Rare myocarditis/cardiomyopathy early; less likely after years of stability
- GI hypomotility more commonly causes constipation than true dysphagia

Why it fits poorly
- Does not explain APS or prior extensive PE.
- Does not convincingly explain the severe pulmonary vascular physiology.

Still important because
- Clozapine + fluvoxamine can markedly raise clozapine levels.
- It may contribute to the dysphagia or aspiration risk.


5) Interstitial lung disease from an autoimmune process

Why it fits
- Restriction + low DLCO + dysphagia suggests CTD-ILD.

Why not enough
- The prior major PE and RV dilation remain central.
- Need HRCT chest data; without it, this remains possible but unproven.


The key pivot in the case

The major pivot is:

A patient with proven APS and prior extensive bilateral PE now has progressive dyspnea with a profoundly reduced DLCO and RV involvement — this should immediately pivot the evaluation toward chronic thromboembolic pulmonary hypertension, even if another autoimmune process may be coexisting.

A second pivot is the addition of dysphagia, which should prevent premature closure and push you to ask:
- Is there an occult connective tissue disease, especially systemic sclerosis?
- Or is dysphagia medication-related / structural / neuromuscular and separate?


Most important next diagnostic move

Urgent evaluation for CTEPH at a pulmonary hypertension center, starting with:

  1. Transthoracic echocardiogram
  2. V/Q scan
    - Best screening test for chronic thromboembolic disease
  3. If abnormal/suspicious: Right heart catheterization + pulmonary angiographic evaluation

This is the highest-yield next step because it addresses the most dangerous and most established likely diagnosis.


Most important management move

Reassess anticoagulation strategy in APS.

Given APS with major thrombotic disease and symptoms despite apixaban-era progression/history, I would strongly consider that she may need transition to warfarin unless there is a compelling reason not to, particularly if she is high-risk APS. This should be done thoughtfully and with specialist input, but it is a major management issue in this case.


What else should be done next, in parallel

Because dysphagia may represent the clue to a second unifying autoimmune disease:


Why I would not prematurely close on scleroderma

Because the APS + prior extensive PE + severe DLCO reduction + RV findings already provide a strong, dangerous, and testable cardiopulmonary diagnosis. Dysphagia may be a coexisting clue, but the immediate threat is pulmonary vascular disease.


Teaching pearl

In a patient with persistent dyspnea after pulmonary embolism, especially with APS, a very low DLCO and RV abnormalities should trigger a workup for CTEPH — and the screening test of choice is a V/Q scan, not a CT pulmonary angiogram alone.

If you want, I can next give a problem representation + illness script + stepwise diagnostic plan for Stage 2.

Round 2

User: Stage 2: Exam + Basic Labs
Sixteen months after her initial hospitalization, her dyspnea has worsened significantly. She now reports dysphagia specifically to liquids (not solids) and extreme fatigue with minor activities like brushing her teeth or making her bed.
Physical Exam: Afebrile, HR 92 bpm, BP 125/84 mmHg, SpO2 85% on room air. She is tachypneic with scattered rhonchi in both lungs. JVP is elevated.
Neurologic Exam: Mild dysarthria. Motor exam shows symmetric weakness in neck flexion (Grade 3/5), shoulder abduction (Grade 4/5), and hip flexion (Grade 3/5). No ptosis or ophthalmoparesis. Deep-tendon reflexes are normal (2+).
Basic Labs: WBC 13,800/µL, Hb 14.2 g/dL, Platelets 362,000/µL. NT-proBNP 4,366 pg/mL (Elevated). Troponin I is normal. Creatine Kinase (CK) is 137 U/L (Normal), Aldolase is 6.9 U/L (Normal).

Resident:

Hello, Chief Resident here.

The clinical picture has shifted dramatically with the physical exam findings. We are no longer looking at a purely cardiopulmonary vascular process. The presence of symmetric proximal muscle weakness (neck flexors, hips, shoulders) and dysarthria in the setting of dysphagia to liquids points toward a neuromuscular or myogenic etiology.

Key Updated Findings:

  1. Proximal Myopathy: Grade 3-4/5 weakness in a "limb-girdle" distribution plus neck flexors.
  2. Bulbar Symptoms: Dysarthria and dysphagia to liquids (suggesting oropharyngeal/palatal weakness).
  3. Right Heart Failure: Elevated JVP, tachypnea, and significantly elevated NT-proBNP (4,366 pg/mL) with hypoxia (SpO2 85%).
  4. Normal Muscle Enzymes: CK and Aldolase are notably normal despite significant clinical weakness.
  5. Long-term Clozapine/Fluvoxamine: Potential for drug-induced complications or interactions.

Clinical Analysis:

The "normal CK" myopathy is a critical branch point. While inflammatory myopathies (Dermatomyositis/Polymyositis) usually elevate CK, they can occasionally present with normal levels, especially in late-stage or specific subtypes (e.g., Antisynthetase syndrome). However, the combination of proximal weakness, bulbar involvement, and severe cardiopulmonary decline in a patient with APS and Clozapine use raises a high suspicion for Myasthenia Gravis (MG) or a Clozapine-induced systemic inflammatory response/myocarditis.

Importantly, APS is associated with other autoimmune diseases. The "restrictive" PFTs and low DLCO might not be ILD or CTEPH alone, but rather respiratory muscle weakness (Shrinking Lung Syndrome or simply diaphragmatic weakness).

Differential Diagnoses:

  1. Myasthenia Gravis (MG) (40%): Explains the liquid dysphagia, dysarthria, and proximal weakness. MG can be associated with other autoimmune conditions (APS). The "restrictive" PFTs and low DLCO can be a "pseudo-restriction" due to poor inspiratory effort.
  2. Inflammatory Myopathy (e.g., Polymyositis or Antisynthetase Syndrome) (25%): Can cause proximal weakness, dysphagia, and ILD (explaining the PFTs). CK can be normal in some cases of dermatomyositis or if the process is very chronic.
  3. Clozapine-Induced Myopathy/Polyserositis (15%): Clozapine is associated with rare but severe systemic inflammatory syndromes and myotoxicity. The interaction with Fluvoxamine (a potent CYP1A2 inhibitor) can lead to toxic Clozapine levels.
  4. Lambert-Eaton Myasthenic Syndrome (LEMS) (10%): Less likely given the bulbar involvement (more common in MG), but causes proximal weakness.
  5. CTEPH with secondary Myopathy (10%): While CTEPH explains the NT-proBNP and prior PE, it does not explain the neck flexor weakness or dysarthria.

Recommended Next Steps & Prioritised Tests:

  1. Acetylcholine Receptor (AChR) and MuSK Antibodies: To confirm Myasthenia Gravis.
  2. Repetitive Nerve Stimulation (RNS) or Single-Fiber EMG: To evaluate for a neuromuscular junction defect.
  3. Clozapine Serum Level: To assess for toxicity due to the Fluvoxamine interaction.
  4. Extended Myositis Antibody Panel: (e.g., Jo-1, Mi-2, SRP, TIF1-gamma) to look for CK-normal inflammatory myopathy.
  5. Echocardiogram (Repeat): To differentiate between RV failure from PH vs. potential Clozapine-induced cardiomyopathy/myocarditis (though Troponin was normal).

Chief Resident's Question: Does the weakness fluctuate throughout the day or worsen with repetitive use (fatigability)? Also, are there any signs of heliotrope rash or Gottron papules on exam?

Attending:

Hello Attending Consultant here.

Critique of the Chief Resident’s plan (6 points):

  1. Probability weighting is inverted: Proximal-predominant weakness, neck flexor involvement, bulbar symptoms, normal CK/aldolase, and markedly elevated NT-proBNP with hypoxia in a patient with documented prior PE and APS make anti-SRP or HMGCR-negative immune-mediated necrotizing myopathy (IMNM) with associated pulmonary hypertension or systemic sclerosis–myositis overlap far more likely than MG (which rarely causes such severe DLCO reduction or right-heart strain without thymoma).

  2. Failure to integrate restrictive physiology correctly: The PFT pattern (TLC 63 %, VC 57 %, DLCO 26 %) plus neck/hip flexor weakness strongly suggests diaphragmatic and respiratory muscle involvement rather than primary ILD or isolated CTEPH; this should elevate shrinking-lung–like physiology or myopathic respiratory failure on the differential ahead of MG.

  3. Omission of critical drug toxicity assessment: Clozapine 500 mg/day with concomitant fluvoxamine (potent CYP1A2 inhibitor) produces supratherapeutic levels in >80 % of such combinations; immediate trough level plus ECG for QTc and echocardiogram for clozapine cardiomyopathy are mandatory before neuromuscular junction testing.

  4. Suboptimal serologic sequence: AChR/MuSK antibodies and EMG are reasonable but lower yield than myositis-specific antibody panel (anti-SRP, anti-Ku, anti-PM-Scl, anti-MDA5) and ANA with centromere/Scl-70 given the APS–myositis–PH overlap syndromes; normal CK does not exclude IMNM.

  5. Missing hemodynamic staging: NT-proBNP 4366 pg/mL, JVP elevation, and room-air desaturation demand same-admission right-heart catheterization with pulmonary vasoreactivity testing rather than “repeat echo” alone; this distinguishes Group 1 PAH, Group 3 PH from myopathy, and CTEPH.

  6. Incomplete dysphagia characterization: Liquid-predominant dysphagia with dysarthria and neck flexor weakness points to pharyngeal and suprahyoid muscle failure; urgent videofluoroscopic swallow study plus high-resolution esophageal manometry should precede antibody results to prevent aspiration.

Revised immediate actions: Obtain clozapine level, full myositis autoantibody panel, HRCT chest, same-admission RHC, and swallow evaluation; deprioritize MG testing until above data return.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

The case has now pivoted away from “just PE/CTEPH” toward an autoimmune myopathy/overlap connective tissue disease causing bulbar + respiratory muscle weakness, with pulmonary hypertension/right-heart failure.

My best current unifying diagnosis is:

Systemic sclerosis–myositis overlap syndrome (scleromyositis) or related inflammatory myopathy overlap, with pulmonary hypertension and pharyngo-esophageal/respiratory muscle involvement.

Why this is now strongest:
- Dysphagia to liquids → strongly suggests oropharyngeal/pharyngeal muscle dysfunction, not mechanical esophageal obstruction.
- Mild dysarthria + symmetric neck flexor/proximal weakness → classic for myopathic bulbar/proximal weakness.
- Normal CK and aldolase do not exclude inflammatory myopathy, especially overlap syndromes and chronic disease.
- Restrictive PFTs may reflect respiratory muscle weakness, not just ILD.
- Severely reduced DLCO and elevated NT-proBNP/JVP/hypoxemia indicate significant pulmonary hypertension/right ventricular strain.
- Dysphagia + PH + myopathy is a very plausible scleroderma-spectrum overlap pattern.

This does not eliminate CTEPH; rather, it suggests the full syndrome may be:
1. APS-associated thromboembolic pulmonary vascular disease, and/or
2. CTD-associated pulmonary hypertension, plus
3. Autoimmune myopathy causing bulbar and respiratory weakness

So the most accurate framing is probably an overlap autoimmune cardiopulmonary-neuromuscular syndrome, not a single isolated diagnosis.


Top differentials

1) Scleromyositis / systemic sclerosis–myositis overlap

Most likely current unifier.

Why it fits
- Dysphagia is very common in systemic sclerosis and overlap myositis.
- Neck flexor and proximal weakness fit inflammatory/overlap myopathy well.
- Pulmonary hypertension is a major complication of systemic sclerosis spectrum disease.
- CK can be normal in overlap myositis.
- Severe fatigue and dyspnea may be compounded by respiratory muscle weakness.

What is missing
- We still need exam/history for Raynaud’s, skin thickening, telangiectasias, reflux, digital changes.
- No serologies yet.

Why still #1
It is the best fit for liquid dysphagia + dysarthria + proximal/neck weakness + PH physiology.


2) Inflammatory myopathy with bulbar/respiratory involvement

Includes polymyositis-spectrum, immune-mediated necrotizing myopathy, overlap myositis.

Why it fits
- Symmetric proximal weakness
- Neck flexor weakness
- Bulbar involvement
- Respiratory muscle weakness can cause restrictive pattern and dyspnea

Why less ideal than scleromyositis specifically
- Does not by itself explain pulmonary hypertension as elegantly unless there is overlap CTD or ILD.
- Normal CK is possible but makes classic necrotizing myopathy less straightforward.


3) CTEPH from APS

Still very important, but no longer sufficient as the main unifier.

Why it fits
- APS
- Prior extensive PE
- Severe DLCO reduction
- Elevated JVP, hypoxemia, high NT-proBNP → significant right-heart strain/PH

Why it does not fully fit now
- It does not explain neck flexor weakness, hip/shoulder weakness, dysarthria, or liquid dysphagia.
- So CTEPH may be coexisting and still critical, but probably not the whole story.


4) Myasthenia gravis

Needs consideration because of bulbar symptoms and normal CK.

Why it fits
- Dysarthria
- Dysphagia to liquids
- Proximal weakness can occur
- Normal CK is expected

Why it fits less well
- No ptosis or ophthalmoparesis
- Weakness pattern sounds more fixed myopathic than fluctuating fatigable NMJ disease
- Does not explain the pulmonary vascular history, very low DLCO, RV strain, or APS connection nearly as well
- Reflexes are normal, which is fine for MG, but the total syndrome still points more toward inflammatory overlap disease

Bottom line
Important differential, but not my leading one.


5) Clozapine/fluvoxamine-related toxicity

Important contributor, unlikely full unifier.

Why it matters
- Fluvoxamine can greatly increase clozapine levels
- Could worsen sedation, swallowing dysfunction, aspiration risk, and possibly cardiopulmonary status indirectly

Why it is not the main diagnosis
- Does not explain the broader autoimmune-thromboembolic pattern
- Does not convincingly explain proximal neck/hip weakness syndrome with PH


Why normal CK does not rule out myositis

This is a major diagnostic trap.


The key pivot in the case

The key pivot is:

Liquid dysphagia + dysarthria + symmetric neck flexor/proximal weakness transforms the case from isolated pulmonary vascular disease into a neuromuscular/autoimmune overlap syndrome.

That is the major turning point.

Earlier, CTEPH was the dominant explanation for dyspnea. Now, the weakness pattern says:
- There is likely respiratory muscle involvement
- Dysphagia is likely oropharyngeal/myopathic
- A connective tissue disease overlap must be actively sought


Most important next diagnostic move

The single most important next diagnostic move is:

Urgent inpatient evaluation of both respiratory failure and swallowing safety, while simultaneously defining the cause of pulmonary hypertension.

If I must choose one immediate bedside move:

Perform a swallow/aspiration safety assessment and monitor respiratory muscle strength

But in parallel, the most important disease-defining testing is:
1. Echocardiogram
2. V/Q scan
3. Right-heart catheterization if PH is confirmed/suspected
4. Autoimmune/myositis serologies
- ANA
- Centromere
- Scl-70
- PM-Scl
- Ku
- myositis panel
5. MRI or EMG if needed to confirm myopathy
6. Videofluoroscopic swallow study


Most important management move

Admit and treat this as a potentially unstable multisystem disease:

If inflammatory overlap myositis becomes strongly supported, immunosuppressive therapy may be needed, but I would not start blindly without stronger evidence unless she is clearly deteriorating from presumed autoimmune muscle disease.


Practical ranking of what fits best now

  1. Scleromyositis / CTD overlap with PH
  2. Inflammatory myopathy with bulbar/respiratory involvement
  3. CTEPH from APS as coexisting major pathology
  4. Myasthenia gravis
  5. Medication-related contribution

Teaching pearl

Normal CK does not exclude inflammatory myopathy—especially in overlap syndromes. In a patient with liquid dysphagia, dysarthria, neck flexor weakness, and restrictive physiology, think bulbar and respiratory muscle involvement even when enzymes are normal.

If you want, I can next synthesize this into a stage-by-stage diagnostic schema and predict the most likely Stage 3

Round 3

User: Stage 3: Advanced Labs + Imaging
Serum Protein Electrophoresis (SPEP) with immunofixation reveals an IgM-λ monoclonal gammopathy.
Chest CT Angiography: Shows patchy peripheral air-space disease at the bases but NO evidence of acute pulmonary embolism.
Echocardiogram: Normal LV function, but severe RV dysfunction with an estimated RV systolic pressure of 78 mmHg.
Right Heart Catheterization: Mean pulmonary artery pressure 51 mmHg, PCWP 11 mmHg, Cardiac Index 1.4 L/min/m², and PVR 16 Wood units (indicating severe precapillary pulmonary hypertension and cardiogenic shock).
Autoimmune Serology: ANCA titer 1:320 (atypical perinuclear pattern), MPO 21 U/mL (Mildly elevated), PR3 10 U/mL (Normal). dsDNA 27 IU (Borderline), RF 130 IU (Elevated). Anti-CCP, Jo-1, and Scl-70 are negative.

Resident:

Resident:
Hello, Chief Resident here.

The clinical picture has evolved into a life-threatening state of cardiogenic shock from severe precapillary pulmonary hypertension (PH), complicated by a systemic autoimmune/paraproteinemic process. The combination of IgM-λ monoclonal gammopathy, severe PH, and myopathic weakness is the key to unlocking this case.

Key Updated Findings:

  1. Severe Precapillary PH: RHC confirms a mean PAP of 51 mmHg with a very high PVR (16 Wood units) and a dangerously low Cardiac Index (1.4 L/min/m²). This is not just "mild" PH; it is advanced right heart failure.
  2. IgM-λ Monoclonal Gammopathy: This is a critical pivot. IgM paraproteins are associated with specific systemic syndromes, including Waldenström macroglobulinemia and rare paraneoplastic neuromuscular/vascular syndromes.
  3. Atypical p-ANCA/MPO Positivity: While MPO is mildly elevated, the "atypical" pattern and the presence of RF and borderline dsDNA suggest a broader autoimmune milieu, possibly secondary to a lymphoproliferative process or a specific overlap syndrome.
  4. Absence of Acute PE: CTPA rules out new large clots, making the PH either Group 1 (PAH) or Group 4 (CTEPH from prior events).
  5. Neuromuscular Involvement: The proximal weakness and bulbar symptoms remain unexplained by the RHC findings, confirming a multi-system disease.

Clinical Analysis:

The presence of IgM monoclonal gammopathy in a patient with severe pulmonary hypertension and neuromuscular symptoms strongly suggests POEMS syndrome (though usually IgG/IgA and associated with polyneuropathy) or, more specifically, TEMPI syndrome (Telangiectasias, Erythropoietin elevation, Monoclonal gammopathy, Perinephric fluid, and Intrapulmonary shunting). However, TEMPI usually features shunting (low PVR), whereas this patient has high PVR.

Another critical consideration is IgM-associated AL Amyloidosis, which can cause both myopathy (pseudohypertrophy or infiltration) and severe pulmonary vascular involvement, though isolated pulmonary vascular amyloid is rare.

The most striking "fit" for IgM gammopathy + severe PH + autoimmune features is Schnitzler Syndrome or a related B-cell dyscrasia-associated vasculopathy. However, we must also consider Antisynthetase Syndrome (despite negative Jo-1, as other antibodies like PL-7/PL-12 were not tested) or Systemic Sclerosis overlap given the RF and ANCA.

Differential Diagnoses:

  1. IgM-Related Systemic Disease / Amyloidosis (35%): IgM-λ can lead to AL amyloidosis. Amyloid infiltration of the pulmonary vasculature can cause severe precapillary PH, and muscle infiltration causes a "pseudomyopathy" with weakness and normal CK.
  2. Systemic Sclerosis / Myositis Overlap (30%): Despite negative Scl-70/Jo-1, the clinical triad of PH, dysphagia, and proximal weakness is classic. The ANCA/MPO/RF positivity supports a systemic autoimmune process.
  3. CTEPH (Group 4 PH) secondary to APS (20%): The RHC is consistent with CTEPH. The weakness and IgM gammopathy would have to be viewed as co-morbidities or paraneoplastic phenomena.
  4. POEMS-like Variant or TEMPI Syndrome (10%): These plasma cell dyscrasias are known to cause unexplained pulmonary hypertension and neuromuscular symptoms.
  5. ANCA-Associated Vasculitis (AAV) (5%): MPO-positivity can be seen in limited forms of vasculitis, but it rarely presents with isolated severe PH and proximal myopathy.

Recommended Next Steps & Prioritised Tests:

  1. Bone Marrow Biopsy and Aspiration: To characterize the IgM-λ source (e.g., Waldenström’s, MGUS, or Plasma Cell Dyscrasia).
  2. Abdominal Fat Pad or Bone Marrow Biopsy for Congo Red Staining: To evaluate for AL Amyloidosis.
  3. Extended Myositis Panel: Testing for PL-7, PL-12, EJ, OJ, and especially anti-Ku or anti-PM-Scl (common in scleroderma-myositis overlap).
  4. Serum Free Light Chain (SFLC) Assay: To calculate the kappa/lambda ratio.
  5. VEGF Level: To screen for POEMS syndrome, which is strongly associated with monoclonal gammopathy and PH.

Chief Resident's Question: Are there any physical findings we missed, such as skin hemangiomas, telangiectasias, or hepatosplenomegaly? Also, what was the hemoglobin/erythropoietin level (looking for TEMPI)?

Attending:

Hello Attending Consultant here.

Critique of the Chief Resident’s plan (6 points):

  1. Mis-ranked leading diagnosis: Severe precapillary PH (mPAP 51 mmHg, PVR 16 WU, CI 1.4) on background of documented APS with prior massive PE plus current CTPA showing no acute embolus but basal peripheral opacities makes operable CTEPH (Group 4 PH) the dominant process until proven otherwise; amyloid or POEMS variants remain lower probability without supporting end-organ findings.

  2. Incomplete integration of neuromuscular findings: Proximal weakness, neck flexor involvement, liquid dysphagia, and dysarthria with normal CK/aldolase plus restrictive PFTs are best explained by respiratory and bulbar myopathy from CTD overlap (scleromyositis or anti-PM-Scl syndrome) rather than amyloid infiltration; this demands anti-PM-Scl, anti-Ku, and anti-RNP serologies ahead of VEGF or broad POEMS workup.

  3. Suboptimal gammopathy evaluation: SPEP/immunofixation showing IgM-λ requires immediate serum viscosity, cryoglobulins, and MYD88 L265P mutation testing to exclude Waldenström-related hyperviscosity or cold-agglutinin vasculopathy before bone-marrow biopsy; amyloid staining is premature without free-light-chain ratio or cardiac MRI.

  4. Missing hemodynamic operability assessment: RHC data already confirm severe PH with low CI; next step is urgent referral for digital-subtraction pulmonary angiography and balloon pulmonary angioplasty evaluation at an expert CTEPH center, not “extended myositis panel” in isolation.

  5. Inadequate APS re-stratification: Confirmed lupus anticoagulant plus borderline dsDNA, elevated RF, and mild MPO elevation suggest possible secondary APS within lupus-overlap or mixed CTD; repeat triple APS antibody panel (including β2-glycoprotein I IgG/IgM) and consideration of warfarin transition from apixaban are mandatory.

  6. Omission of swallow safety and respiratory mechanics: Liquid dysphagia with bulbar weakness and CI 1.4 demands immediate bedside swallow evaluation, supine FVC/NIF measurement, and non-invasive ventilation planning to avert hypercapnic failure before serologic or marrow results return.

Revised priorities: Urgent CTEPH-team referral with pulmonary angiogram, full CTD overlap serologies (PM-Scl, Ku, RNP), serum viscosity/free light chains, swallow study, and therapeutic anticoagulation reassessment; deprioritize amyloid/POEMS testing unless above data support.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

Severe precapillary pulmonary hypertension, most likely CTEPH from APS, with a concurrent autoimmune overlap myopathy causing bulbar and proximal weakness.

Most likely full synthesis:
- Primary life-threatening process: CTEPH / chronic thromboembolic pulmonary hypertension due to APS
- Concurrent second process: CTD-overlap myopathy, especially scleromyositis/PM-Scl-Ku-RNP spectrum, causing:
- liquid dysphagia
- dysarthria
- neck flexor/proximal weakness
- restrictive physiology from respiratory muscle weakness

I would not force the IgM-λ monoclonal gammopathy to be the unifying explanation yet. At this stage it is important, but may be an incidental or secondary clue rather than the main diagnosis.


Why CTEPH is now the leading cardiopulmonary diagnosis

The hemodynamics are decisive:
- mPAP 51 mmHg
- PCWP 11 mmHg
- PVR 16 WU
- CI 1.4 L/min/m²

This is severe precapillary PH with low-output right-heart failure/cardiogenic shock.

Why CTEPH fits best:
- She has established APS
- She had extensive bilateral acute PE previously
- She now has severe RV dysfunction
- CTA showing no acute PE does not exclude chronic thromboembolic disease
- APS is a classic substrate for persistent/recurrent thromboembolic pulmonary vascular obstruction

A V/Q scan and expert CTEPH imaging review remain essential because CTA is not sufficiently sensitive to exclude chronic disease.


Why this is not explained by PH alone

Pulmonary hypertension does not explain:
- dysphagia specifically to liquids
- mild dysarthria
- neck flexor weakness
- proximal hip/shoulder weakness
- normal reflexes, no ocular findings

That cluster strongly suggests bulbar + proximal myopathic involvement, not simply deconditioning or RV failure.


Best explanation for the neuromuscular syndrome

CTD overlap myopathy, especially scleromyositis / PM-Scl-Ku-RNP spectrum

This remains the best fit.

Why it fits
- Dysphagia and dysarthria → pharyngeal muscle involvement
- Neck flexor + proximal symmetric weakness → inflammatory/overlap myopathy pattern
- CK and aldolase can be normal
- Severe pulmonary disease can coexist through:
- respiratory muscle weakness
- CTD-related PH
- autoimmune overlap with APS

Why despite negative Scl-70 and Jo-1
- Negative Scl-70 does not exclude systemic sclerosis
- Negative Jo-1 does not exclude inflammatory myositis or overlap syndromes
- The relevant antibodies now are:
- PM-Scl
- Ku
- U1-RNP
- centromere
- broader myositis panel


How to interpret the autoimmune serologies

Why ANCA vasculitis is not the leading diagnosis


Role of the IgM-λ monoclonal gammopathy

This is important but should not derail the case.

It could represent:

  1. MGUS
  2. Waldenström-spectrum lymphoplasmacytic disorder
  3. Less likely a paraprotein-related systemic syndrome

Why it is not yet the best unifier

Still important next checks


Top differentials

1) CTEPH due to APS — leading cardiopulmonary diagnosis

Fits
- APS
- prior extensive PE
- severe precapillary PH
- RV failure

Against
- Doesn’t explain weakness/dysphagia

2) Scleromyositis / CTD-overlap myopathy — leading neuromuscular diagnosis

Fits
- bulbar symptoms
- neck/proximal weakness
- normal CK possible
- can coexist with PH and APS

Against
- no classic skin/vascular CTD findings presented yet
- serologies incomplete

3) Systemic sclerosis with PAH plus overlap myopathy

Fits
- PH + dysphagia + myopathy is very compatible
- Scl-70 negativity does not exclude it

Against
- APS/PE history makes CTEPH still more compelling for the PH mechanism

4) Myasthenia gravis

Fits
- liquid dysphagia
- dysarthria
- normal CK

Against
- no ptosis/ophthalmoparesis
- weakness pattern feels more myopathic
- does not unify PH well

5) Paraproteinemia-related disease: Waldenström/amyloid/other

Fits
- IgM-λ monoclonal gammopathy is real and potentially relevant

Against
- currently lacks supportive organ pattern
- less parsimonious than APS + CTD overlap


Key pivot in the case

The key pivot is that RHC confirms severe low-output precapillary pulmonary hypertension, while the neuromuscular/bulbar syndrome remains real and separate.

So the case is best understood as:
- a hemodynamic emergency from severe PH/right-heart failure
- plus
- a parallel autoimmune neuromuscular process

That is the pivot away from trying to force one exotic explanation for everything.


Most important next diagnostic move

Immediate expert CTEPH evaluation

Specifically:
- V/Q scan
- Expert pulmonary angiographic review / digital subtraction angiography if needed
- assessment for:
- pulmonary endarterectomy
- balloon pulmonary angioplasty
- PH-targeted therapy as bridge/support

This is the highest-priority disease-defining next step because it addresses the immediately life-threatening and potentially treatable cause of shock physiology.


Most important next management move

Stabilize severe RV failure / cardiogenic shock in a pulmonary hypertension center

This patient has:
- severe RV dysfunction
- CI 1.4
- hypoxemia
- high PVR

So the most important move is:
- urgent transfer/management in a PH-expert ICU/center
- oxygen
- careful volume management
- RV-supportive therapy
- consider PH-directed rescue therapy under specialist supervision
- evaluate urgently for CTEPH intervention

Also crucial:
- Reassess anticoagulation — in APS with major thrombosis, warfarin is generally preferred over apixaban, especially if there is concern for recurrent or unresolved thromboembolic disease.


Important parallel next steps

For the myopathy/bulbar syndrome

For paraprotein

- serum free light chains

Round 4

User: Stage 4: Specialized Neuro Investigation
Given the persistent weakness despite hemodynamic stabilization on heparin and milrinone, further neuro workup was initiated.
NCS/EMG: Sensory and motor nerve conduction studies are normal. Repetitive nerve stimulation is normal (no decremental response). Needle EMG shows fibrillation potentials, positive sharp waves, and early recruitment of small, polyphasic myopathic motor units in the proximal leg muscles.
MRI Proximal Left Leg: Shows diffuse global muscle atrophy with significant muscle edema (bright signal on STIR sequences).

Resident:

Resident:
Hello, Chief Resident here.

The specialized neuro investigation has provided the definitive evidence needed to categorize the neuromuscular component of this case. We are no longer speculating about a neuromuscular junction disorder; we have objective proof of an active, inflammatory, or necrotizing myopathy.

Key Updated Findings:

  1. Needle EMG: Shows classic myopathic features (small, polyphasic units) with spontaneous activity (fibrillations, positive sharp waves), indicating an active, irritable myopathic process.
  2. MRI Leg: Confirms diffuse muscle edema (STIR positivity), which is the hallmark of active inflammatory myositis or immune-mediated necrotizing myopathy (IMNM).
  3. Normal NCS/RNS: Effectively rules out Myasthenia Gravis, LEMS, and peripheral neuropathy.
  4. Hemodynamic Context: The patient is in a precarious state, requiring Milrinone (inotropic support) and Heparin (bridging from Apixaban), confirming the severity of her right-heart failure/cardiogenic shock.

Clinical Synthesis:

The patient has a dual-catastrophe presentation:
1. Severe CTEPH/PH (Group 4 or 1): Likely driven by her APS, leading to right-heart failure.
2. Active Inflammatory Myopathy: Causing bulbar (dysphagia/dysarthria), respiratory, and proximal limb weakness.

The presence of IgM-λ monoclonal gammopathy and atypical p-ANCA/MPO in this context points toward a specific overlap syndrome. While "Jo-1" was negative, the clinical triad of PH, myositis, and dysphagia is highly suggestive of Anti-PM-Scl or Anti-Ku associated overlap (Scleromyositis). However, we must also consider Anti-SRP or Anti-HMGCR myopathy, though these usually have much higher CK levels.

Differential Diagnoses:

  1. Scleromyositis (Systemic Sclerosis-Polymyositis Overlap) (50%): This is the most cohesive diagnosis. It explains the severe PH (either via CTD-PAH or overlap with APS-CTEPH), the liquid dysphagia (pharyngeal myopathy), the neck/proximal weakness, and the restrictive PFTs. The normal CK is well-documented in scleroderma-associated myopathy.
  2. Immune-Mediated Necrotizing Myopathy (IMNM) (20%): (e.g., Anti-SRP). Can cause severe weakness and dysphagia. While CK is usually high, it can be lower in chronic or partially treated phases.
  3. Antisynthetase Syndrome (Non-Jo-1) (15%): (e.g., Anti-PL-7, PL-12). These often present with ILD and myositis with lower CK levels than Jo-1.
  4. Paraneoplastic Myopathy / IgM-Related Syndrome (10%): The IgM-λ could indicate an underlying lymphoproliferative disorder triggering a paraneoplastic myositis.
  5. Amyloid Myopathy (5%): While MRI shows edema (more typical of myositis), amyloid can occasionally mimic inflammatory signals, though it usually presents with a "pseudohypertrophy" rather than atrophy.

Recommended Next Steps & Prioritised Tests:

  1. Extended Myositis-Specific Antibody Panel: Must include Anti-PM-Scl (75 and 100), Anti-Ku, Anti-U1-RNP, Anti-SRP, and Anti-HMGCR.
  2. Muscle Biopsy: To differentiate between inflammatory myositis (T-cell infiltrates) and necrotizing myopathy (pauci-immune necrosis), and to stain for amyloid (Congo Red) given the IgM-λ.
  3. V/Q Scan (if stable): To definitively assess the contribution of CTEPH to her PH, as this dictates surgical (Endarterectomy) vs. medical management.
  4. Serum Free Light Chain Ratio and Bone Marrow Biopsy: To characterize the IgM-λ monoclonal gammopathy and rule out Waldenström’s or Amyloidosis.
  5. Video Fluoroscopic Swallow Study (VFSS): To characterize the mechanics of her liquid dysphagia and prevent aspiration pneumonia while in shock.

Chief Resident's Question: Given the severe PH and myositis, is there any evidence of "Mechanic's hands," Raynaud's, or nailfold capillary changes on a more detailed re-examination? These would clinch the Scleromyositis/Antisynthetase diagnosis.

Attending:

Hello Attending Consultant here.

Critique of the Chief Resident’s plan (6 points):

  1. Probability inversion persists: EMG/MRI-proven active myopathy (fibrillations, STIR edema) plus severe precapillary PH (mPAP 51, PVR 16, CI 1.4) on APS background with prior massive PE makes CTEPH-driven Group 4 PH with concurrent scleromyositis overlap (PM-Scl or Ku) the dominant diagnosis; ranking scleromyositis at 50% while relegating CTEPH to a secondary consideration underestimates immediate hemodynamic mortality risk.

  2. Incomplete serologic prioritization: Extended myositis panel is appropriate but must explicitly include anti-PM-Scl-75/100, anti-Ku, anti-RNP, and anti-MDA5 before anti-SRP/HMGCR or VEGF; negative Scl-70/Jo-1 does not exclude overlap, yet atypical pANCA/MPO plus RF still requires repeat lupus anticoagulant/β2-GPI to re-stratify APS phenotype.

  3. Delayed operability assessment: RHC already confirms severe PH with shock physiology on milrinone; urgent digital-subtraction pulmonary angiography and CTEPH-center referral for potential pulmonary thromboendarterectomy or balloon pulmonary angioplasty must precede muscle biopsy or marrow studies, as CI 1.4 precludes safe elective procedures.

  4. Omitted drug toxicity reconciliation: Persistent weakness despite hemodynamic stabilization on heparin/milrinone demands immediate clozapine trough level (fluvoxamine interaction) and ECG/troponin trend to exclude ongoing clozapine cardiomyopathy or serositis contributing to both myopathy and PH.

  5. Suboptimal dysphagia and respiratory evaluation: Liquid dysphagia with bulbar myopathy plus low CI requires same-day fiberoptic endoscopic evaluation of swallow (FEES) and supine FVC/NIF/ABG to quantify neuromuscular respiratory failure risk before video fluoroscopy or antibody results.

  6. Premature amyloid/POEMS focus: IgM-λ gammopathy warrants free light-chain assay and viscosity but bone-marrow biopsy and Congo-red staining remain low-yield until after PH operability is addressed and overlap serologies return; paraneoplastic myopathy is possible but less likely than CTD overlap given EMG/MRI pattern.

Revised priorities: Immediate CTEPH-team transfer with pulmonary angiogram, full overlap autoantibody panel (PM-Scl/Ku/RNP), clozapine level, FEES/NIF, and therapeutic anticoagulation optimization (warfarin preferred in APS); defer biopsy and marrow until above data stabilize the patient.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

Dual pathology:
1. Severe CTEPH from APS causing precapillary PH and RV failure
2. Active inflammatory myopathy, most likely CTD-overlap myositis (scleromyositis/PM-Scl-Ku-RNP spectrum), causing bulbar, proximal, and likely respiratory muscle weakness

Stage 4 essentially confirms that the weakness is true myopathy:
- Normal NCS/RNS argues against MG/LEMS/peripheral neuropathy
- Needle EMG shows irritable myopathy
- MRI shows muscle edema, supporting active inflammatory myositis

So the case is no longer primarily diagnostic uncertainty about the neuro syndrome. The remaining task is subtyping the myopathy and not losing sight of the hemodynamic emergency.


Why this is the best synthesis

Myopathy is now proven

Findings:
- Fibrillations + positive sharp waves
- Early recruitment
- Small polyphasic myopathic motor units
- Diffuse STIR muscle edema

This is classic for active inflammatory/irritable myopathy, not neuromuscular junction disease and not simple deconditioning.

PH remains severe and likely thromboembolic until proven otherwise

She still has:
- APS
- prior massive bilateral PE
- severe precapillary PH with low CI
- RV failure

That remains most consistent with CTEPH, even if some CTD-associated PH may coexist.


Top differentials for the myopathy

1) Scleromyositis / systemic sclerosis-overlap myositis

Best current myopathy subtype.

Why it fits
- Bulbar symptoms: liquid dysphagia, dysarthria
- Proximal + neck flexor weakness
- CK can be normal
- Often overlaps with pulmonary vascular disease
- Can present without classic Scl-70 positivity

What would support it
- PM-Scl, Ku, U1-RNP, centromere positivity
- Raynaud’s, nailfold capillary changes, reflux, skin thickening, telangiectasias


2) Overlap inflammatory myopathy not yet fully classified

A practical second choice.

Why it fits
- EMG/MRI clearly show active myositis
- Bulbar involvement is common in overlap myositis
- Autoimmune background is strong

Why less specific
- We do not yet have defining serologies or biopsy


3) Immune-mediated necrotizing myopathy

Possible but less favored.

Why it fits
- Can cause profound proximal weakness
- EMG/MRI may look similar

Why less likely
- CK is usually markedly elevated
- Bulbar-predominant features and overlap-autoimmune context point elsewhere


4) Antisynthetase-spectrum myositis

Still possible despite negative Jo-1.

Why it fits
- Myositis can occur with negative Jo-1 if PL-7/PL-12/EJ/OJ etc.
- Pulmonary disease overlap possible

Why less likely
- Dysphagia + PH + normal CK feels more overlap/scleromyositis than classic antisynthetase
- No mechanic’s hands or ILD-defining story yet


5) Paraprotein-related myopathy / amyloid

Lower probability.

Why it stays on list
- IgM-λ monoclonal gammopathy is real

Why it is less favored
- EMG/MRI pattern is very compatible with inflammatory myositis
- Clinical phenotype is better explained by autoimmune overlap
- No stronger amyloid clues yet


What now does not fit well

Myasthenia gravis

Now much less likely:
- Normal repetitive nerve stimulation
- Needle EMG and MRI point to muscle disease
- No ocular signs

Pure CTEPH as sole diagnosis

No longer plausible as the only explanation:
- Cannot explain bulbar + proximal weakness pattern
- Cannot explain myopathic EMG/MRI


Key pivot in the case

The key pivot is:

Stage 4 proves the weakness is an active inflammatory myopathy, not NMJ disease and not just consequence of cardiopulmonary illness.

That means the case is definitively two intersecting disease processes unless a single overlap CTD ends up linking both.


Most important next diagnostic move

Send the right serologies and get tissue only if needed

Highest-yield next diagnostic step for the myopathy:
- PM-Scl-75/100
- Ku
- U1-RNP
- Centromere
- Expanded myositis panel including MDA5, PL-7, PL-12, EJ, OJ, SRP, HMGCR

Muscle biopsy

Important if serologies are nondiagnostic or treatment decisions need confirmation.
Biopsy can distinguish:
- overlap myositis
- necrotizing myopathy
- vasculitic myopathy
- amyloid/infiltrative disease

But if she is unstable, biopsy should not delay treatment of the more life-threatening cardiopulmonary disease.


Most important management move

Treat this as both:

Immediate priorities:
1. CTEPH expert evaluation
- V/Q if not done
- pulmonary angiographic assessment
- determine candidacy for pulmonary endarterectomy or balloon pulmonary angioplasty
2. Aspiration and respiratory muscle protection
- FEES or videofluoroscopic swallow assessment
- NIF, upright/supine FVC, ABG if needed
3. Anticoagulation optimization
- In APS, likely transition toward warfarin rather than DOAC-based long-term therapy
4. Rheumatology-guided immunotherapy
- Once infectious mimics are excluded and phenotype is sufficiently supported, consider high-dose glucocorticoids with steroid-sparing strategy tailored to subtype
- Be cautious: in systemic sclerosis-spectrum disease, steroid use carries risk, but active disabling myositis may still require treatment


Why not wait too long on immunotherapy

She has:
- proven active myopathy
- bulbar symptoms
- probable respiratory muscle involvement

If this is inflammatory overlap myositis, delay risks:
- aspiration
- further muscle loss
- prolonged respiratory weakness

Still, treatment should be coordinated carefully because the PH/RV failure picture is fragile.


Teaching pearl

Normal CK does not exclude clinically important inflammatory myopathy. When EMG shows irritable myopathy and MRI shows STIR muscle edema, the diagnosis is muscle inflammation until proven otherwise—even in a patient whose dyspnea initially seemed fully cardiopulmonary.

If you want, I can now give the single best final diagnosis most likely revealed in the eventual case resolution, plus the specific antibody/biopsy result I would predict next.

Round 5

User: Stage 5: Final Results
A muscle biopsy of the left quadriceps was performed.
Histopathology: Modified Gomori trichrome staining on thin frozen sections (3-µm) reveals fibers with multiple intracytoplasmic granular and rod-shaped inclusions. No inflammatory infiltrates or vacuolar changes.
Immunofluorescence: The rods stain positive for α-actinin-3.
Diagnosis: Sporadic Late-Onset Nemaline Myopathy (SLONM) associated with Monoclonal Gammopathy.

Resident:

Resident:
Hello, Chief Resident here.

This is a remarkable and rare diagnosis that elegantly unifies the monoclonal gammopathy, the normal CK, and the severe, progressive neuromuscular decline.

Key Final Findings:

  1. Muscle Biopsy: The presence of intracytoplasmic rod-shaped inclusions (Nemaline rods) on Gomori trichrome, staining positive for α-actinin-3, is pathognomonic for Nemaline Myopathy.
  2. SLONM-MG: The "Sporadic Late-Onset" variant (SLONM) is specifically associated with Monoclonal Gammopathy of Undetermined Significance (MGUS), typically of the IgM or IgG type.
  3. Clinical Correlation: SLONM-MG is notorious for presenting with subacute, progressive proximal weakness, neck flexor weakness, and bulbar involvement (dysphagia/dysarthria), often with a normal or only mildly elevated CK.
  4. Respiratory Failure: SLONM-MG frequently involves the diaphragm and accessory muscles, explaining the restrictive PFTs and the patient's severe dyspnea.

Clinical Synthesis:

The patient’s presentation was a "perfect storm" of two distinct but potentially related pathologies. While the APS and prior PE caused the severe CTEPH (explaining the RHC findings and RV failure), the SLONM-MG was the driver of her dysphagia, neck weakness, and respiratory muscle failure.

There is an emerging recognition that SLONM-MG may have an autoimmune basis related to the monoclonal protein. Interestingly, some cases of SLONM have been associated with other autoimmune phenomena, though the link to APS specifically is less well-defined in the literature.

Final Diagnosis:

Sporadic Late-Onset Nemaline Myopathy (SLONM) associated with IgM-λ Monoclonal Gammopathy, co-existing with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) secondary to Antiphospholipid Antibody Syndrome (APS).

Management Implications:

  1. Treatment of SLONM-MG: This is a critical pivot. SLONM associated with monoclonal gammopathy is often refractory to standard steroids but can respond dramatically to Autologous Stem Cell Transplantation (ASCT) or Chemotherapy (e.g., Bortezomib-based regimens) aimed at the plasma cell/B-cell clone. IVIG may provide temporary stabilization.
  2. Management of CTEPH: The patient remains in a high-risk state (CI 1.4). She requires urgent evaluation for Pulmonary Thromboendarterectomy (PTE) or Balloon Pulmonary Angioplasty (BPA), alongside optimized anticoagulation (transitioning to Warfarin).
  3. Respiratory Support: Given the diaphragmatic involvement of SLONM, she likely needs long-term nocturnal NIV or close monitoring of respiratory mechanics.

Teaching Pearl:

Sporadic Late-Onset Nemaline Myopathy (SLONM) should be considered in any adult presenting with progressive proximal and neck flexor weakness with a normal CK, especially if a monoclonal gammopathy is present. It is a rare but treatable "myopathy mimic" where the treatment is directed at the underlying hematologic clone rather than traditional immunosuppression.

Attending:

Hello Attending Consultant here.

Critique of the proposed plan (6 points):

  1. Diagnostic closure is premature: SLONM-MG explains the EMG, MRI, biopsy, normal CK, bulbar/proximal weakness, and IgM-λ gammopathy, but does not account for the severe precapillary PH (mPAP 51 mmHg, PVR 16 WU, CI 1.4) or documented prior massive bilateral PE in confirmed APS; these require independent CTEPH confirmation via V/Q scan and pulmonary angiography before labeling as “co-existing.”

  2. Underestimates respiratory muscle overlap: SLONM classically causes diaphragmatic involvement leading to true neuromuscular restrictive failure; the original PFTs (TLC 63%, VC 57%, DLCO 26%) and current hypoxemia must be reinterpreted with supine FVC/NIF data rather than attributing all to CTEPH or ILD.

  3. Anticoagulation recommendation incomplete: APS with lupus anticoagulant and major prior PE favors lifelong warfarin (target INR 2–3 or higher) over apixaban; heparin bridge is appropriate acutely, but transition plan and anti-Xa monitoring (given potential lupus anticoagulant interference) are mandatory.

  4. SLONM therapy sequencing flawed: While ASCT or bortezomib-based clone-directed therapy is first-line for SLONM-MG, initiation must follow hemodynamic stabilization and CTEPH operability assessment; high-dose steroids or IVIG may be temporizing bridges but carry risk in severe RV failure.

  5. Missing multidisciplinary integration: Urgent concurrent referral to CTEPH/PH expert center, hematology (for clone characterization, free light chains, MYD88, bone marrow), and rheumatology (to exclude occult PM-Scl/Ku overlap despite biopsy) is required; swallow evaluation and NIV planning remain time-sensitive.

  6. Omitted clozapine reconciliation: Long-term clozapine (500 mg/day) plus fluvoxamine interaction must have trough level checked; drug-induced myopathy or cardiomyopathy can mimic or coexist with SLONM and may necessitate dose reduction or discontinuation under psychiatry supervision.

Revised priorities: Immediate CTEPH imaging/hemodynamic re-evaluation with angiography, warfarin optimization, serum free light chains/bone marrow, swallow/NIF assessment, and hematology-led clone-directed therapy planning once RV output stabilizes.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

Sporadic late-onset nemaline myopathy (SLONM) associated with IgM-λ monoclonal gammopathy, causing:
- proximal and neck flexor weakness
- dysarthria
- dysphagia to liquids
- respiratory muscle involvement with restrictive physiology
- normal CK/aldolase
- myopathic EMG and muscle edema on MRI

This is now biopsy-proven by:
- nemaline rods on Gomori trichrome
- α-actinin-positive rod inclusions

Full final synthesis

This case is best understood as two major concurrent diseases:

  1. SLONM associated with monoclonal gammopathy
    - explains the neuromuscular syndrome and likely much of the restrictive physiology

  2. Severe precapillary pulmonary hypertension, most likely CTEPH from APS
    - explains the RV failure, high PVR, low CI, elevated JVP, profound NT-proBNP, and prior PE history

SLONM is the answer to the “mystery weakness,” but it does not fully explain the documented severe pulmonary vascular disease.


Why SLONM fits so well

Classic fitting features:
- adult onset
- progressive proximal weakness
- neck flexor weakness
- bulbar symptoms
- respiratory muscle involvement
- normal CK
- EMG showing irritable myopathy
- MRI with muscle edema/atrophy
- monoclonal gammopathy

This is almost a textbook phenotype for SLONM-MGUS/monoclonal gammopathy–associated SLONM.


Why earlier alternatives fell away

Myasthenia gravis

Did not fit because:
- no ocular findings
- normal repetitive nerve stimulation
- biopsy proved structural myopathy

CTD-overlap myositis

Reasonable earlier, but biopsy did not show inflammatory infiltrates; instead it showed nemaline rods, which is decisive.

ANCA vasculitis

Serologies were nonspecific and never matched the syndrome well.

Amyloid/paraprotein infiltrative myopathy

Possible thought with monoclonal protein, but biopsy established SLONM specifically.


The key pivot in the case

The key pivot was not the autoimmune serologies—it was the combination of:
- normal CK despite clear weakness
- bulbar/neck flexor involvement
- EMG-confirmed irritable myopathy
- MRI muscle edema
- monoclonal gammopathy

That pattern should strongly raise SLONM, especially once more common inflammatory myopathies and NMJ disorders are excluded.

The final decisive pivot, of course, was the muscle biopsy showing nemaline rods.


Most important next management move

Hematology-directed clone therapy for SLONM associated with monoclonal gammopathy

This is the critical disease-specific move.

In SLONM with monoclonal gammopathy, outcomes are best when treatment is directed at the plasma cell/monoclonal clone, rather than treating it like routine inflammatory myositis alone.

Typical approaches include:
- autologous stem cell transplantation (ASCT) in eligible patients
- or plasma cell–directed chemotherapy such as bortezomib-based regimens

Supportive/bridging therapy may include:
- IVIG in selected cases
- respiratory support
- nutrition/swallow support


Most important parallel management issue

Do not lose sight of the pulmonary hypertension

She still has:
- severe precapillary PH
- RV failure/shock physiology
- APS with prior major PE

So parallel urgent management remains:
- expert CTEPH evaluation
- lifelong APS-appropriate anticoagulation, usually warfarin
- pulmonary hypertension center care
- assessment for endarterectomy or balloon pulmonary angioplasty if CTEPH is confirmed


Why this case is so instructive

Because SLONM can masquerade as:
- inflammatory myopathy
- myasthenia
- deconditioning
- CTD overlap disease

And it often has:
- normal CK
- bulbar symptoms
- respiratory weakness
- monoclonal gammopathy

Those clues should trigger biopsy consideration early.


Teaching pearl

In an adult with progressive proximal and neck weakness, bulbar symptoms, normal CK, and a monoclonal gammopathy, think SLONM and obtain a muscle biopsy—because treatment is often clone-directed, not standard myositis therapy.

Top 15 Takeaways for Clinicians

  1. A unilateral pleural effusion with significant weight loss in an elderly patient is malignant until proven otherwise. Subacute cough, unilateral effusion, and 10.4 kg weight loss demand urgent diagnostic thoracentesis.
  2. Diagnostic thoracentesis with Light criteria plus cytology, AFB, and GeneXpert should be performed before contrast CT. Fluid analysis classifies the effusion and screens for malignancy and TB simultaneously.
  3. Complete lobar consolidation with mucus plugging on CT signals an obstructing endobronchial lesion. Post-obstructive atelectasis sharply elevates the probability of bronchogenic carcinoma.
  4. "Unclassified cells" comprising 54% of pleural fluid nucleated cells demand urgent flow cytometry. These are likely malignant cells, atypical plasma cells, or lymphoma cells requiring immunophenotyping.
  5. Atypical plasma cells in pleural fluid constitute a diagnosis-changing finding. This pivots the case toward a plasma cell neoplasm; SPEP, UPEP, immunofixation, and serum free light chains become the immediate priority.
  6. A second FDG-avid extranodal mass with pleural plasmacytosis strongly suggests extramedullary plasma cell disease. Multifocal lesions in the aerodigestive tract and pleura point to disseminated extramedullary plasmacytoma.
  7. Flow cytometry showing IgM-lambda restriction with low marrow plasma cells and negative MYD88 L265P defines extramedullary IgM plasmacytoma. This excludes both classic myeloma (CD19-negative) and Waldenström macroglobulinemia (MYD88-mutated).
  8. An IgM M-spike demands immediate serum viscosity measurement regardless of marrow burden. IgM is a pentamer with high intrinsic viscosity; hyperviscosity risk is independent of plasma cell percentage.
  9. MYD88 L265P mutation testing distinguishes Waldenström from IgM myeloma and extramedullary plasmacytoma. Its absence with low marrow infiltration and extranodal disease redirects the diagnosis.
  10. A normal CBC and normal renal function do not exclude multiple myeloma or plasma cell dyscrasia. The elevated globulin gap (total protein 8.0 with normal albumin) was an early clue.
  11. Travel history with persistent diarrhea must keep TB on the differential even after plasma cells are found. Atypical plasma cells can be reactive in chronic infections; prove monoclonality with flow cytometry and exclude TB.
  12. Sinus biopsy with full IHC is required to distinguish extramedullary plasmacytoma from lymphoma with plasmacytic differentiation. Flow cytometry alone on pleural fluid cannot substitute for tissue histology.
  13. Bone marrow biopsy showing under 5% plasma cells with extramedullary disease defines extramedullary plasmacytoma, not myeloma. The marrow is the defining compartment.
  14. PET-CT should follow, not precede, serum protein studies and tissue biopsy when plasma cell dyscrasia is suspected. Ordering PET-CT before SPEP risks anchoring on FDG-avid lesions without knowing the underlying process.
  15. An IgM monoclonal plasma cell process that is extranodal, marrow-sparing, and MYD88-negative is extramedullary plasmacytoma—a rare but treatable entity. Treatment with localized radiotherapy or clone-directed therapy differs from both lung cancer and standard myeloma regimens.